JP2005519052A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005519052A5 JP2005519052A5 JP2003557553A JP2003557553A JP2005519052A5 JP 2005519052 A5 JP2005519052 A5 JP 2005519052A5 JP 2003557553 A JP2003557553 A JP 2003557553A JP 2003557553 A JP2003557553 A JP 2003557553A JP 2005519052 A5 JP2005519052 A5 JP 2005519052A5
- Authority
- JP
- Japan
- Prior art keywords
- hours
- pravastatin
- formulation
- release
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 76
- 229960002965 pravastatin Drugs 0.000 claims 76
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 76
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 238000009472 formulation Methods 0.000 claims 28
- 239000000203 mixture Substances 0.000 claims 28
- 238000004090 dissolution Methods 0.000 claims 16
- 239000011248 coating agent Substances 0.000 claims 10
- 238000000576 coating method Methods 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 230000001419 dependent effect Effects 0.000 claims 9
- 210000000813 small intestine Anatomy 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 7
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 210000002784 stomach Anatomy 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 206010013710 Drug interaction Diseases 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 108010023302 HDL Cholesterol Proteins 0.000 claims 2
- 108010028554 LDL Cholesterol Proteins 0.000 claims 2
- 239000003524 antilipemic agent Substances 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 229920000080 bile acid sequestrant Polymers 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34777502P | 2002-01-11 | 2002-01-11 | |
| US40726902P | 2002-09-03 | 2002-09-03 | |
| PCT/IB2003/000336 WO2003057195A1 (en) | 2002-01-11 | 2003-01-10 | Pravastatin pharmaceutical formulations and methods of their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005519052A JP2005519052A (ja) | 2005-06-30 |
| JP2005519052A5 true JP2005519052A5 (https=) | 2006-01-05 |
Family
ID=26995414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003557553A Pending JP2005519052A (ja) | 2002-01-11 | 2003-01-10 | プラバスタチン医薬製剤及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6967218B2 (https=) |
| EP (1) | EP1465605A1 (https=) |
| JP (1) | JP2005519052A (https=) |
| AU (1) | AU2003201735B2 (https=) |
| CA (1) | CA2473106A1 (https=) |
| IL (1) | IL162937A0 (https=) |
| MX (1) | MXPA04006780A (https=) |
| NO (1) | NO20043333L (https=) |
| WO (1) | WO2003057195A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04006780A (es) * | 2002-01-11 | 2005-06-08 | Athpharma Ltd | Formulaciones farmaceuticas de pravastatina y metodos para usarlas. |
| AU2002244881A1 (en) * | 2002-03-22 | 2003-10-08 | Ranbaxy Laboratories Limited | Controlled release drug delivery system of pravastatin |
| SI21400A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska družba d.d. | Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze |
| US8987322B2 (en) | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| CN101262851A (zh) * | 2004-01-20 | 2008-09-10 | 诺瓦提斯公司 | 直接压片配方和方法 |
| DK1715893T3 (da) * | 2004-01-20 | 2009-11-09 | Novartis Pharma Ag | Direkte kompressionsformulering og fremgangsmåde |
| EP1563837A1 (en) * | 2004-02-03 | 2005-08-17 | Ferrer Internacional, S.A. | Hypocholesterolemic compositions comprising a statin and an antiflatulent agent |
| CA2588215A1 (en) * | 2004-11-22 | 2006-05-26 | Dexcel Pharma Technologies Ltd. | Controlled absorption of statins in the intestine |
| GR1006879B (el) * | 2005-09-14 | 2010-07-13 | "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., | Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουν αναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων |
| US20100055173A1 (en) * | 2006-10-10 | 2010-03-04 | Adel Penhasi | Release of statins in the intestine |
| GB0713707D0 (en) * | 2007-07-13 | 2007-08-22 | Generics Uk Ltd | Stable compositions |
| US20090226516A1 (en) * | 2008-03-04 | 2009-09-10 | Pharma Pass Ii Llc | Sartan compositions |
| US20090226515A1 (en) * | 2008-03-04 | 2009-09-10 | Pharma Pass Ii Llc | Statin compositions |
| US20130142849A1 (en) * | 2010-08-17 | 2013-06-06 | Lupin Limited | Controlled release formulations of dronedarone |
| EP2692354A1 (en) | 2012-08-03 | 2014-02-05 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Means for treating heart disease |
| JP2021517141A (ja) * | 2018-03-09 | 2021-07-15 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 心血管疾患のための組み合わせ治療 |
| CN111803462A (zh) * | 2020-07-15 | 2020-10-23 | 浙江诺得药业有限公司 | 一种普伐他汀钠肠溶片及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4904474A (en) * | 1988-01-25 | 1990-02-27 | Alza Corporation | Delivery of drug to colon by oral disage form |
| US5180589A (en) * | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
| US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
| US4997658A (en) * | 1988-11-21 | 1991-03-05 | Merck & Co., Inc. | Method for enhancing the lowering of plasma cholesterol levels |
| US5376383A (en) * | 1988-11-21 | 1994-12-27 | Merck & Co., Inc. | Method for enhancing the lowering of plasma-cholesterol levels |
| CA2045428A1 (en) * | 1990-06-26 | 1991-12-27 | Alfred W. Alberts | Method for enhancing the lowering of plasma cholesterol levels |
| US5916595A (en) * | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
| UA69413C2 (uk) * | 1998-05-22 | 2004-09-15 | Брістол-Майерс Сквібб Компані | Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції |
| UA73092C2 (uk) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| WO2000033821A1 (en) * | 1998-12-07 | 2000-06-15 | Bristol-Myers Squibb Company | Enteric coated pravastatin bead formulation |
| SI20109A (sl) | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| US6962717B1 (en) * | 1999-01-29 | 2005-11-08 | Disphar International B.V. | Pharmaceutical compositions |
| US6569461B1 (en) * | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
| CA2404044A1 (en) * | 2000-04-11 | 2001-10-18 | Atherogenics, Inc. | Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality |
| US6936731B2 (en) * | 2000-10-05 | 2005-08-30 | TEVA Gyógyszergyár Részvénytársaság | Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same |
| US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| MXPA04006780A (es) * | 2002-01-11 | 2005-06-08 | Athpharma Ltd | Formulaciones farmaceuticas de pravastatina y metodos para usarlas. |
-
2003
- 2003-01-10 MX MXPA04006780A patent/MXPA04006780A/es unknown
- 2003-01-10 JP JP2003557553A patent/JP2005519052A/ja active Pending
- 2003-01-10 WO PCT/IB2003/000336 patent/WO2003057195A1/en not_active Ceased
- 2003-01-10 US US10/339,487 patent/US6967218B2/en not_active Expired - Fee Related
- 2003-01-10 EP EP03700436A patent/EP1465605A1/en not_active Withdrawn
- 2003-01-10 IL IL16293703A patent/IL162937A0/xx unknown
- 2003-01-10 AU AU2003201735A patent/AU2003201735B2/en not_active Ceased
- 2003-01-10 CA CA002473106A patent/CA2473106A1/en not_active Abandoned
-
2004
- 2004-08-10 NO NO20043333A patent/NO20043333L/no not_active Application Discontinuation
-
2005
- 2005-08-17 US US11/205,028 patent/US20050277691A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005519052A5 (https=) | ||
| ES2401598T3 (es) | Composiciones farmacéuticas estables que contienen ácidos 7-sustituido-3,5-dihidroxiheptanoicos o ácidos 7-sustituido-3,5-dihidroxiheptenoicos | |
| JP2004511521A (ja) | 回腸胆汁輸送の阻害化合物とＨＭＧ−ＣｏＡレダクターゼ阻害剤を含んでなる経口製剤 | |
| HK1259458A1 (zh) | 用於治疗心血管疾病的吉卡宾组合 | |
| JPH0710773B2 (ja) | 一定の放出性及び即時放出性を有する薬物粒子 | |
| CN105473145A (zh) | 用于加速斑块消退的组合物和治疗方法 | |
| JP2005528430A5 (https=) | ||
| US20060251720A1 (en) | Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins | |
| JP2023057082A (ja) | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 | |
| CN105120845A (zh) | 药物组合药物 | |
| CN105473144A (zh) | 用于加速斑块消退的组合物和治疗方法 | |
| RS53084B (sr) | Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4, kao što je roflumilast, roflumilast-n-oksid za lečenje inflamatornih plućnih obolenja | |
| JP2003513038A (ja) | ホスホジエステラーゼ４阻害剤の投与法 | |
| JP2009525265A5 (https=) | ||
| KR20110011643A (ko) | 변형 방출 니아신 배합물 | |
| CN101795684A (zh) | 他汀类化合物与抗肥胖药的组合 | |
| JPH0710772B2 (ja) | 一定の放出性を保持した薬物粒子 | |
| JP2007526277A (ja) | 経口投与を目的としたトルペリゾンの徐放性医薬組成物 | |
| ES2361284T3 (es) | Combinaciones terapéuticas. | |
| US20140314844A1 (en) | Oral complex formulation comprising omega-3 fatty acid and hmg-coa reductase inhibitor with improved stability | |
| ES2314693T3 (es) | Composicion farmaceutica que contiene psicoestimulantes. | |
| CN105431140B (zh) | 含有缓释二甲双胍和速释HMG-CoA还原酶抑制剂的复合制剂 | |
| US20090226515A1 (en) | Statin compositions | |
| CN102271507A (zh) | 分泌型磷脂酶a2(spla2)抑制剂和烟酸药物组合物以及治疗心血管疾病和血脂异常的方法 | |
| KR20210093900A (ko) | 젬카빈, 이의 약학적으로 허용가능한 염, 이의 조성물 및 이의 사용 방법 |